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KEY LEARNING POINTS
Sweet syndrome is a rare inflammatory disease that is 
marked by abrupt onset of painful erythematous plaques or 
nodules and often accompanied by fever and leukocytosis.  
While there is considered to be three types of Sweet’s 
syndrome; classical, malignancy associated, and drug-
induced, the most common type remains classical4.  Classical 
Sweet’s syndrome is associated most commonly with URI or 
GI infections, inflammatory bowel disease, or pregnancy 
though less frequent associations exist with several other 
medical conditions. Malignancy associated Sweet’s syndrome 
is most commonly associated with hematologic malignancies 
however it has been detected in solid tumor cancer as well. 
Drug-induced Sweet Syndrome has been associated with 
several medications however Granulocyte-colony stimulating 
factor is the most commonly recognized6.  Sweet syndrome 
can develop in any age patient, although age 30-60 is most 
common for classical. In Classical Sweet syndrome, 80% of 
cases have been in women.  in women. 
History
Patient is a 44 year old male who presented with an area of painful 
erythema on the dorsum of right ankle, left ankle and foot, back of 
neck, and dorsal bilateral middle fingers extending to wrists. 
All the above joints painful to move, and difficult to ambulate. The 
area on the back of his neck and occipital scalp were last to erupt 
and are not as painful. 
+Fatigue, malaise, subjective chills
No new medications
No fever (+subjective chills), no abdominal 
pain/nausea/vomit/diarrhea/constipation
PMH: HIV (last viral load 84copies/ml 2018), syphilis (distantly 
treated),Type 2 Diabetes Mellitus, social anxiety, low testosterone, 
hyperlipidemia
Medications: abacavir-dolutegravir-lamivudine, atorvastatin, 
bupropion, fluoxetine, semaglutide, testosterone cypionate IM 
Physical Exam
128/72, 96, 16, 98.3F, O2 98%RA. 226lb 12.8oz, 5ft 11.5in
Gen: well nourished, appears fatigued but no acute distress
HEENT: oral mucosa moist/pink without lesions. Neck supple, no 
lymphadenopathy except bilateral <1cm moveable occipital nodes
Extremities:  Right wrist with dorsal erythema, mild edema, bilateral 
middle digits with mild edema and violaceous skin discoloration. 
MCP, wrists and ankles with bilateral erythema, stiff and painful on 
active and passive rom
Skin: see above for skin changes overlying joints. Neck and occipital 
scalp with erythematous plaques with raised well-defined borders. No 
fluctuence or tenderness in this area. Skin changes overlying joints 
painful to palpation (see photos)
Assessment/Plan
44 year old HIV positive male distantly treated for syphilis, with new 
onset rash, chills and polyarthritis/polyarthralgias
Differential diagnosis included vasculitis, syphilis, reactive arthritis, 
sweet’s syndrome
Biopsy obtained of right ankle and neck lesions
RPR titer, cbc with differential, cmp, blood cultures, CRP, HIV RNA
Outcome/Follow up
Biopsy: neutrophilic dermatosis consistent with Sweet’s 
Syndrome. Pertinent lab data: RPR 1:2, CRP 32.9 mg/dl, WBC 
14.5.
Treatment: Oral prednisone 1 mg/kg/day. Within three days, the 
patient had clinical improvement. Prednisone was tapered over six 
weeks and the patient’s rash and symptoms did not recur.
Once a diagnosis of Sweet’s syndrome is established, management should focus on identifying 
underlying infection or disease processes, eliminating any precipitating drug exposure, and 
evaluation for malignancy including age-appropriate screening.  Corticosteroid therapy is the first-
line treatment for Sweet’s syndrome and often induces rapid clinical response.  Oral prednisone 
started at 0.5 to 1mg/kg per day often produces clinical improvement within 48 hours and lesions 
often resolve within 2 weeks.  After the disease is controlled, the prednisone dose can be tapered 
over 4-6 weeks (1).  Although most patients will need systemic corticosteroids, a minority with 
small localized cutaneous lesions may respond to high dose topical steroids.  When avoidance of 
systemic corticosteroids is needed, alternative first line therapies include colchicine, dapsone and 
potassium iodide have efficacy based on case reports and retrospective studies (2). 
This case provides an excellent example of Sweet’s 
Syndrome and its clinical considerations.  A 44 year old 
male HIV positive patient presented with arthralgias, chills, 
malaise and a plaque-like rash on the back of his neck, 
head and wrist.  The biopsy confirmed neutrophilic
dermatosis consistent with Sweet’s Syndrome.  It is 
extremely important to consider the possible causes of 
Sweet’s Syndrome, while the diagnosis is being established 
and treatment is initiated.  Our patient was up to date on 
preventative cancer screening for his age, and thorough 
physical exam did not reveal any suspicion for occult 
malignancy.  He had no antecedent or concurrent acute 
infection to precipitate Sweet’s Syndrome. With respect to 
medications, Abacavir is known to cause neutrophilic
dermatosis, but the patient had been on this medication for 
greater than one year, and there was not a strong temporal 
relationship between drug initiation and onset of symptoms.  
Additional evidence against Abacavir as a causative agent 
included no recurrence when prednisone was tapered even 
though patient was continued on Abacavir.  There are few 
case reports of Sweet’s Syndrome associated with HIV 
infection, but a causal relationship has not been established 
(3).  Consideration was given to syphilis infection, but 
patient was previously treated and had no increase in his 
titers.  The clinical opinion of our team and the consulting 
dermatologist was that this case was idiopathic. 
Consider Sweet’s Syndrome in the differential diagnosis of any 
patient who presents with the abrupt onset of painful 
erythematous papules, plaques or nodules.  
Major diagnostic criteria: 
1) Abrupt onset of painful erythematous plaques or nodules. 
2) Histopathologic evidence of dense neutrophilic infiltrate 
without evidence of leukocytoclastic vasculitis.  
Minor diagnostic criteria (need two): 
1) Pyrexia >38C. 
2) Association with underlying hematologic or visceral 
malignancy, inflammatory disease for pregnancy, or 
preceded by URI or vaccination.
3) Excellent response to treatment with systemic 
glucocorticoids or potassium iodide. 
4) Abnormal lab studies
The mainstay of treatment is corticosteroids and improvement 
is often seen within 48 hours.  Steroid dose is tapered over 4 to 
6 weeks.  
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